Industry news

Global type 1 diabetes mellitus market value to exceed $7 billion by 2021

European Pharmaceutical Review

The type 1 diabetes mellitus market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK and Japan will expand from $4.2 billion in 2014 to $7.1 billion by 2021, according to business intelligence provider GBI Research.

Healthcare ad and media agencies break into annual 'best workplaces' ranking

Beth Snyder Bulik / FiercePharmaMarketing

Two healthcare agencies made a noteworthy list this week. And while it was only two, it still points to how pharma marketing is moving more mainstream as healthcare and prescription drugs infiltrate the daily political and cultural conversation.

China healthcare reforms in gear, but not fast enough for some

EJ Lane / FeircePharmaAsia

China is moving on several fronts to make it easier and safer for potential patients to use the nation's expanding healthcare system, with a new emphasis on drug regulations, devices and elderly care. Even so, American drugmakers say the government should do even more in the drugs area.

FDA report detailing faulty lab tests adds to pressure for increased regulation of diagnostics

Varun Saxena / FierceMedicalDevices

The FDA's drive to regulate the molecular diagnostics industry is gaining steam. It finally provided specific examples of problematic tests in a report to Congress. The agency has made several general statements about inaccurate diagnostics over the years without naming any specific tests or providers.

Better together? Savvy e-patients may make pharma marketing smarter

Beth Snyder Bulik / FiercePharmaMarketing

First came key opinion leaders. Then digital KOLs. Now, e-patients may be just what the doctor ordered for pharma marketing. But in the way that not just any doctor qualifies for a speaking role, e-patients aren't just any patients. "Patient leaders are the equivalent of physician key opinion leaders in the patient world," said Jack Barrette, founder and CEO of WeGo Health, a social network for health influencers that also matches its members with pharma and healthcare companies.

MIT researchers develop ingestible real-time vital sign monitor

Stacy Lawrence / Fierce Medical Devices

Ingestible drug monitoring is already on its way--with the first drug to incorporate the technology already being considered by the FDA alongside a nod earlier this year for the tech itself from Proteus. And ingestible imaging was approved by the FDA last year with PillCam, which is now owned by Medtronic. The latest ingestible tech that may be up next before the regulator could be vital sign monitoring.

EU study using nanoparticles, low-dose radiation to aid companion diagnostics in battling cancer

Joseph Keenan / FierceMedicalDevice

The European Union is funding a consortium that is looking into combining synthetic nanoparticles or antibodies with low-level radioactive substances to improve the use of companion diagnostics in battling cancer and other diseases.

China to lift IPO ban; slow-queuing pharma may prefer Hong Kong

Pearl Liu and Cornelia Zou / BioWorld

The China Securities Regulatory Commission (CSRC) said Friday it plans to lift the four-month ban on IPOs that started during a bout of extreme volatility in the financial markets in Mainland China throughout June and July.

Bumper haul of expensive new drugs heads to U.S. and Europe

Ben Hirschler / Reuters

Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging.

TEDMED 2015: A brief history of CRISPR and what's next

Stacy Lawrence / Fierce Medical Devices

Only a scant few years old, CRISPR gene editing technology already is heavily weighted with potential implications for human disease and health. It's already being used to more easily and precisely create genetically modified plants and animals. And for the first time last year, CRISPR was used to genetically modify a human embryo.